<DOC>
	<DOCNO>NCT00834704</DOCNO>
	<brief_summary>Open-label , multicenter , dose-escalation , safety , pharmacodynamic , pharmacokinetic study .</brief_summary>
	<brief_title>Safety Study PEGPH20 Given Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This study PEGPH20 human subject design evaluate safety PEGPH20 determine maximum tolerate dose PEGPH20 . All patient receive PEGPH20 . Each group patient receive high dose previous group . This continue group high plan dose completes study group major side effect assign dose .</detailed_description>
	<criteria>Pathologic ( histologic cytologic ) confirmation metastatic locally advanced solid tumor . Patients experience disease progression receive appropriate standard / approve chemotherapy standard palliative treatment measure exist , choose decline standard palliative treatment . One tumor measurable RECIST criterion . Karnofsky performance status â‰¥ 70 % . Recovery toxic effect previous therapy , include radiation , chemotherapy surgery . Negative serum urine pregnancy test result woman childbearing potential . For men woman childproducing potential , agreement use effective contraception ( hormonal barrier birth control abstinence ) time screen study entry throughout study participation . Brain metastasis . New York Heart Association Class III IV cardiac disease , myocardial infarction , cardiac arrhythmia require medical therapy . Known allergy hyaluronidase . Serious nonmalignant disease ( e.g. , hydronephrosis , liver failure , condition include psychiatric illness ) could compromise protocol objective opinion Investigator and/or Sponsor . Women currently breast feed . Concurrent participation interventional therapeutic study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>PEGPH20</keyword>
	<keyword>PEGylated recombinant human hyaluronidase</keyword>
	<keyword>Metastatic locally advance solid tumor</keyword>
</DOC>